{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:36:41Z","timestamp":1793036201730,"version":"4.5.0"},"reference-count":26,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,4,24]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Ibrutinib has limited clinical efficacy in patients with relapsed or refractory peripheral T-cell lymphoma or cutaneous T-cell lymphoma. Ibrutinib inhibits ITK.<\/jats:p>","DOI":"10.1182\/bloodadvances.2017011916","type":"journal-article","created":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T16:00:39Z","timestamp":1524067239000},"page":"871-876","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":25,"title":["Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma"],"prefix":"10.1182","volume":"2","author":[{"given":"Anita","family":"Kumar","sequence":"first","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosha","family":"Vardhana","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison J.","family":"Moskowitz","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Porcu","sequence":"additional","affiliation":[{"name":"The Comprehensive Cancer Center and The James Cancer Hospital and Solove Research Institute, and"},{"name":"Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Dogan","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Dubovsky","sequence":"additional","affiliation":[{"name":"Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Matasar","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Younes","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Horwitz","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2018,4,18]]},"reference":[{"issue":"16","key":"2019111620200427800_B1","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J Clin Oncol"},{"issue":"15","key":"2019111620200427800_B2","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2019111620200427800_B3","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/nri1591","article-title":"TEC-family kinases: regulators of T-helper-cell differentiation","volume":"5","author":"Schwartzberg","year":"2005","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"2019111620200427800_B4","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/ni734","article-title":"Mutation of Tec family kinases alters T helper cell differentiation","volume":"2","author":"Schaeffer","year":"2001","journal-title":"Nat Immunol"},{"issue":"12","key":"2019111620200427800_B5","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1158\/1078-0432.CCR-14-3322","article-title":"The use of transcriptional profiling to improve personalized diagnosis and management of cutaneous T-cell lymphoma (CTCL)","volume":"21","author":"Litvinov","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2019111620200427800_B6","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1124\/mol.112.079889","article-title":"Molecular characteristics of CTA056, a novel interleukin-2-inducible T-cell kinase inhibitor that selectively targets malignant T cells and modulates oncomirs","volume":"82","author":"Guo","year":"2012","journal-title":"Mol Pharmacol"},{"issue":"8","key":"2019111620200427800_B7","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1182\/blood-2006-12-061507","article-title":"Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome","volume":"110","author":"Shin","year":"2007","journal-title":"Blood"},{"issue":"9","key":"2019111620200427800_B8","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1038\/jid.2010.128","article-title":"Eotaxins and CCR3 interaction regulates the Th2 environment of cutaneous T-cell lymphoma","volume":"130","author":"Miyagaki","year":"2010","journal-title":"J Invest Dermatol"},{"issue":"1","key":"2019111620200427800_B9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1046\/j.1365-2567.1997.00325.x","article-title":"Extracorporeal photochemotherapy restores Th1\/Th2 imbalance in patients with early stage cutaneous T-cell lymphoma","volume":"92","author":"Di Renzo","year":"1997","journal-title":"Immunology"},{"issue":"14","key":"2019111620200427800_B10","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1158\/1078-0432.CCR-12-3488","article-title":"TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma","volume":"19","author":"Guenova","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"16","key":"2019111620200427800_B11","doi-asserted-by":"crossref","first-page":"4812","DOI":"10.1158\/1078-0432.CCR-06-0532","article-title":"Th1 response and cytotoxicity genes are down-regulated in cutaneous T-cell lymphoma","volume":"12","author":"Hahtola","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2019111620200427800_B12","doi-asserted-by":"crossref","first-page":"E966","DOI":"10.1073\/pnas.1500712112","article-title":"Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK","volume":"112","author":"Sagiv-Barfi","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"issue":"13","key":"2019111620200427800_B13","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood-2014-08-593137","article-title":"Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma","volume":"125","author":"Sagiv-Barfi","year":"2015","journal-title":"Blood"},{"issue":"22","key":"2019111620200427800_B14","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.LBA-3.LBA-3","article-title":"Multicenter open-label phase 2 study of ibrutinib in chronic graft versus host disease (cGVHD) after failure of corticosteroids [abstract]","volume":"128","author":"Miklos","year":"2016","journal-title":"Blood"},{"issue":"14","key":"2019111620200427800_B15","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1056\/NEJMc1505857","article-title":"Ibrutinib in refractory classic Hodgkin\u2019s lymphoma","volume":"373","author":"Hamadani","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111620200427800_B16","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"18","key":"2019111620200427800_B17","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","article-title":"Clinical end points and response criteria in mycosis fungoides and S\u00e9zary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer","volume":"29","author":"Olsen","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111620200427800_B18","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nri3158","article-title":"Standardizing immunophenotyping for the Human Immunology Project","volume":"12","author":"Maecker","year":"2012","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"2019111620200427800_B19","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1084\/jem.20070663","article-title":"Phenotypic and functional features of human Th17 cells","volume":"204","author":"Annunziato","year":"2007","journal-title":"J Exp Med"},{"issue":"3","key":"2019111620200427800_B20","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1158\/1078-0432.CCR-13-0226","article-title":"Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia--focus on the B-cell receptor","volume":"20","author":"ten Hacken","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2019111620200427800_B21","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1182\/blood-2004-03-1037","article-title":"Anaplastic large cell lymphomas lack the expression of T-cell receptor molecules or molecules of proximal T-cell receptor signaling","volume":"104","author":"Bonzheim","year":"2004","journal-title":"Blood"},{"issue":"1","key":"2019111620200427800_B22","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1146\/annurev-immunol-110416-120628","article-title":"Disorders of the JAK\/STAT pathway in T cell lymphoma pathogenesis: implications for immunotherapy","volume":"35","author":"Waldmann","year":"2017","journal-title":"Annu Rev Immunol"},{"issue":"11","key":"2019111620200427800_B23","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/ng.3415","article-title":"Integrated molecular analysis of adult T cell leukemia\/lymphoma","volume":"47","author":"Kataoka","year":"2015","journal-title":"Nat Genet"},{"issue":"22","key":"2019111620200427800_B24","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood.V128.22.58.58","article-title":"Implications of concurrent ibrutinib therapy on CAR T-cell manufacturing and phenotype and on clinical outcomes following CD19-targeted CAR T-cell administration in adults with relapsed\/refractory CLL [abstract]","volume":"128","author":"Geyer","year":"2016","journal-title":"Blood"},{"issue":"10","key":"2019111620200427800_B25","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1002\/1097-0142(19871115)60:10<2412::AID-CNCR2820601010>3.0.CO;2-F","article-title":"Immunologic abnormalities in angioimmunoblastic lymphadenopathy","volume":"60","author":"Pizzolo","year":"1987","journal-title":"Cancer"},{"issue":"6367","key":"2019111620200427800_B26","doi-asserted-by":"crossref","first-page":"eaan4368","DOI":"10.1126\/science.aan4368","article-title":"The target landscape of clinical kinase drugs","volume":"358","author":"Klaeger","year":"2017","journal-title":"Science"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/8\/871\/880725\/advances011916.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/8\/871\/880725\/advances011916.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T01:20:17Z","timestamp":1573953617000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/2\/8\/871\/15893\/Pilot-trial-of-ibrutinib-in-patients-with-relapsed"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,18]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,4,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2017011916","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,18]]}}}